The clinical trial report, “Gastric Cancer - Global Clinical Trials Review, 2026" provides an overview of Gastric Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Gastric Cancer Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Gastric Cancer
- Mar 24, 2026: First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma
- Mar 17, 2026: Tonix Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the AACR Annual Meeting 2026
- Mar 17, 2026: Henlius Debuts Preclinical Data of Its Proprietary CDH17 ADC, Showing a Differentiated Profile in GI Cancers at ADC Asia Congress 2026
- Mar 16, 2026: Novabridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
- Mar 16, 2026: Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd a sustained-release pre|CISION exatecan peptide-drug conjugate
- Feb 24, 2026: Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis
- Feb 24, 2026: Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma
- Feb 17, 2026: NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined With Immunochemotherapy in Patients With 1L Gastric Cancer
- Feb 12, 2026: CHM CDH17 Advances to Dose Level 3
- Feb 09, 2026: Voluntary Announcement Completion of Subject Enrollment in Phase III Clinical Trial of Tecotabart Vedotin “CLDN18.2 ADC”
- Feb 02, 2026: Imfinzi Perioperative Regimen Recommended for Approval in the EU by CHMP for Patients With Early Gastric and Gastroesophageal Cancers
- Feb 02, 2026: Henlius Holds U.S. Investigator Meeting for HLX22-GC-301, a Head-to-Head Phase 3 Trial vs Standard of Care (±Pembrolizumab) in HER2+ Gastric Cancer
- Jan 28, 2026: Qurebio To Present at ASCO 2026 Its Q-1802 Phase II Clinical Results
- Jan 27, 2026: Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) Were Published in Annals of Oncology
- Jan 16, 2026: Appclon Partner Henlius, Jpmorgan Chase, Confident That AC101 Will Become a Blockbuster as a First-Line Treatment for Gastric Cancer
- Jan 14, 2026: Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer
- Jan 11, 2026: Results From Neoadjuvant Studies of Henlius’ Serplulimab in Colon/Rectal Cancer Released at ASCO GI 2026
- Jan 09, 2026: Henlius Accelerates Global Phase 3 Head-to-Head Development of HLX22 as First-Line Treatment for HER2-Positive Gastric Cancer
- Jan 08, 2026: Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors
- Jan 07, 2026: Study Ties Zanidatamab Combo to 32-Month Median OS in HER2+ Metastatic Gastric Cancer
- Jan 06, 2026: NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
- Clinical Trial Profile Snapshots
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Disclaimer
- Source
- Gastric Cancer Therapeutics, Global, Clinical Trials by Region, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2026*
- Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2026*
- Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials by Phase, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2026*
- Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2026*
- Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck & Co Inc
- Bristol-Myers Squibb Co
- Roche Holding AG
- AstraZeneca Plc
- Jiangsu Hengrui Pharmaceuticals Co Ltd
- Thermo Fisher Scientific Inc
- Sanofi
- Eli Lilly and Co
- IQVIA Holdings Inc
- Pfizer Inc
